search
Back to results

Patient-Customized Bioprinting Technology for Practical Regeneration of the Respiratory Tract (Trachea)

Primary Purpose

Thyroid Cancer

Status
Active
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Three-dimensional patient-specific bioprinting trachea implantation
Sponsored by
Ja Seong Bae, MD, phD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Thyroid Cancer focused on measuring Trachea

Eligibility Criteria

19 Years - 74 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age Range: Individuals between 19 and 75 years of age are eligible for participation. Specific Medical Condition: Patients must meet the following criteria and have thyroid or airway diseases necessitating partial or segmental resection: Thyroid Cancer Patients: For patients with thyroid cancer, inclusion is based on TNM staging, specifically stage II or higher differentiated thyroid cancer patients. Verification of complete removal through a freeze section test during surgery in accordance with the staging system for papillary carcinoma of the trachea is essential (Hum Pathol. 1993 Aug; 24(8):866-70). Patients for whom conventional reconstruction methods, including single-stage anastomosis, are infeasible and require alternative approaches like flap reconstruction. Patients suitable for single anastomosis, but assessed to derive more benefits than risks from 3D bioprinting, considering factors such as post-surgery aftereffects, complications, prolonged recovery, and potential decline in quality of life due to surgical intervention. Defect Size Patients with defects encompassing more than 30% of the cartilage around the affected organ are eligible. Smaller defects may also qualify if reinforcing defects using soft tissue is infeasible due to factors such as surrounding inflammation, tissue instability, tissue adhesion, unstable blood supply, or the anticipation of reoperation during reconstruction. Pregnancy Consideration: In the case of childbearing women, individuals must provide a negative result on a pregnancy test and commit to using contraception throughout the clinical study period. Informed Consent: Participants must voluntarily provide written consent after receiving a comprehensive explanation of the clinical study. Exclusion Criteria: Pregnancy and Lactation: Pregnant or lactating women are excluded from participation in the study. Prior Thyroid or Airway Surgery: Individuals who have undergone thyroid or airway peripheral surgery before undergoing screening are ineligible for participation. Persistent Inflammation: Patients with ongoing inflammation of the thyroid or surrounding tissues at the time of screening are excluded. Systemic Inflammatory Disease: Patients diagnosed with systemic inflammatory diseases at the screening stage are not eligible to participate. Anesthesia Risk Factors: Individuals with a high risk of complications associated with general anesthesia due to existing liver disease, kidney disease, or heart disease are excluded. Sepsis: Patients diagnosed with sepsis at the time of screening are not eligible for participation. Hemorrhage Predisposition: Individuals with a predisposition to hemorrhage at the time of screening are excluded from the study.

Sites / Locations

  • Seoul St. Mary's Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treated

Arm Description

Three-dimensional patient-specific bioprinting trachea implantation

Outcomes

Primary Outcome Measures

airway lumen opening rate
measured by curved laryngeal endoscopy
crust formation degree
measured by curved laryngeal endoscopy
granuloma formation degree
measured by curved laryngeal endoscopy
degree of inflammation
measured by curved laryngeal endoscopy
other relevant findings
measured by curved laryngeal endoscopy

Secondary Outcome Measures

Airway State on CT
airway patency by ratio compared to preoperative state
white blood cell count (WBC)
Serum inflammatory markers
differential white blood cell count (WBC Diff)
Serum inflammatory markers
C-reactive protein (CRP)
Serum inflammatory markers
erythrocyte sedimentation rate (ESR)
Serum inflammatory markers
stability of bronchial wall structure
measured by bronchoscopy
degree of organ opening
measured by bronchoscopy
mucous membrane formation
measured by bronchoscopy
presence of inflammatory or healing tissue
measured by bronchoscopy

Full Information

First Posted
August 29, 2023
Last Updated
September 20, 2023
Sponsor
Ja Seong Bae, MD, phD
Collaborators
Korea Health Industry Development Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT06051747
Brief Title
Patient-Customized Bioprinting Technology for Practical Regeneration of the Respiratory Tract (Trachea)
Official Title
Development of the Practical Usage Based Technology Using the Patient Customized Bioprinting Trachea for the Regeneration of Respiratory Tract (Trachea)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
July 17, 2023 (Actual)
Primary Completion Date
August 16, 2023 (Actual)
Study Completion Date
August 16, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Ja Seong Bae, MD, phD
Collaborators
Korea Health Industry Development Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This clinical trial aims to assess the effectiveness and safety of a novel approach utilizing biopolymers, hydrogels, mucous membranes, and cartilage tissue regeneration cells integrated into 3D bioprinting technology for the creation and implantation of patient-specific tracheal organs.
Detailed Description
Study Objective: This clinical study focuses on patients with thyroid or airway diseases necessitating partial or segmental organ resection. The objective is to evaluate the feasibility, efficacy, and safety of transplanting functional patient-specific bioprinted tracheal organs as an innovative regenerative approach. Patient Enrollment: Patients voluntarily participate and provide written consent. A thorough screening procedure is conducted to determine their eligibility based on selection and exclusion criteria. Bioprinting Process: The study employs cutting-edge bioprinting technology to create complex organ tissues. Specifically, 3D cell printing is employed to fabricate a bioprinted tracheal organ. Stem cells derived from the human nasal cavity and nasal septum cartilage cells are integrated to form a cell-supporting body. Transplantation Procedure: Eligible patients receive transplantation of the functional patient-specific bioprinted trachea. The transplantation aims to restore tracheal functionality and address the unique challenges posed by thyroid and airway diseases. Evaluation and Monitoring: Following transplantation, a comprehensive assessment regimen is undertaken to evaluate both the effectiveness and safety of the procedure. This includes flexural laryngeal endoscopy, bronchoscopy, computed tomography (CT) scans, and laboratory tests. Post-Transplant Measures: To ensure the stability of the transplanted organ immediately after the procedure, neck fixing splints are employed to limit movement. Thyroid Cancer Patients: For patients diagnosed with thyroid cancer, a distinct follow-up protocol is established. A five-year observation period is implemented, extending beyond the standard follow-up for general cancer patients. Additional observations include thyroid ultrasound, Free T4, Thyroid-Stimulating Hormone (TSH), Thyroglobulin Antigen (Thyroglobulin Ag), and Anti-Thyroglobulin Antibody (Anti-TG Ab) tests conducted at the designated observation points. This study seeks to contribute novel insights into the realm of regenerative medicine and enhance the understanding of patient-specific bioprinting technology as a potential solution for tracheal and airway diseases.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Thyroid Cancer
Keywords
Trachea

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Model Description
Treatment group : 1 patient with bioprinted tracheal reconstruction
Masking
None (Open Label)
Allocation
N/A
Enrollment
1 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treated
Arm Type
Experimental
Arm Description
Three-dimensional patient-specific bioprinting trachea implantation
Intervention Type
Procedure
Intervention Name(s)
Three-dimensional patient-specific bioprinting trachea implantation
Intervention Description
The intervention entails the creation of a 3D cell-printed tracheal organ, achieved through the fusion of biopolymer materials and the bioprinting (3D cell printing) technique. This process involves distribution of nasal cavity stem cells (hNTSCs) and nasal septum cartilage cells (hNCs) within hydrogel matrices, culminating in the formation of a personalized tracheal structure.
Primary Outcome Measure Information:
Title
airway lumen opening rate
Description
measured by curved laryngeal endoscopy
Time Frame
1 week, 2 weeks, 4 weeks, 24 weeks, 2 years
Title
crust formation degree
Description
measured by curved laryngeal endoscopy
Time Frame
1 week, 2 weeks, 4 weeks, 24 weeks, 2 years
Title
granuloma formation degree
Description
measured by curved laryngeal endoscopy
Time Frame
1 week, 2 weeks, 4 weeks, 24 weeks, 2 years
Title
degree of inflammation
Description
measured by curved laryngeal endoscopy
Time Frame
1 week, 2 weeks, 4 weeks, 24 weeks, 2 years
Title
other relevant findings
Description
measured by curved laryngeal endoscopy
Time Frame
1 week, 2 weeks, 4 weeks, 24 weeks, 2 years
Secondary Outcome Measure Information:
Title
Airway State on CT
Description
airway patency by ratio compared to preoperative state
Time Frame
4 weeks
Title
white blood cell count (WBC)
Description
Serum inflammatory markers
Time Frame
4 weeks, 48 weeks, 2years
Title
differential white blood cell count (WBC Diff)
Description
Serum inflammatory markers
Time Frame
4 weeks, 48 weeks, 2years
Title
C-reactive protein (CRP)
Description
Serum inflammatory markers
Time Frame
4 weeks, 48 weeks, 2years
Title
erythrocyte sedimentation rate (ESR)
Description
Serum inflammatory markers
Time Frame
4 weeks, 48 weeks, 2years
Title
stability of bronchial wall structure
Description
measured by bronchoscopy
Time Frame
4 weeks, 48 weeks, 2years
Title
degree of organ opening
Description
measured by bronchoscopy
Time Frame
4 weeks, 48 weeks, 2years
Title
mucous membrane formation
Description
measured by bronchoscopy
Time Frame
4 weeks, 48 weeks, 2years
Title
presence of inflammatory or healing tissue
Description
measured by bronchoscopy
Time Frame
4 weeks, 48 weeks, 2years
Other Pre-specified Outcome Measures:
Title
Incidence of Treatment-Emergent Adverse Events
Description
Safety and Tolerability
Time Frame
1 week, 2 weeks, 4 weeks, 24 weeks, 48 weeks, 72 weeks, 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
74 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age Range: Individuals between 19 and 75 years of age are eligible for participation. Specific Medical Condition: Patients must meet the following criteria and have thyroid or airway diseases necessitating partial or segmental resection: Thyroid Cancer Patients: For patients with thyroid cancer, inclusion is based on TNM staging, specifically stage II or higher differentiated thyroid cancer patients. Verification of complete removal through a freeze section test during surgery in accordance with the staging system for papillary carcinoma of the trachea is essential (Hum Pathol. 1993 Aug; 24(8):866-70). Patients for whom conventional reconstruction methods, including single-stage anastomosis, are infeasible and require alternative approaches like flap reconstruction. Patients suitable for single anastomosis, but assessed to derive more benefits than risks from 3D bioprinting, considering factors such as post-surgery aftereffects, complications, prolonged recovery, and potential decline in quality of life due to surgical intervention. Defect Size Patients with defects encompassing more than 30% of the cartilage around the affected organ are eligible. Smaller defects may also qualify if reinforcing defects using soft tissue is infeasible due to factors such as surrounding inflammation, tissue instability, tissue adhesion, unstable blood supply, or the anticipation of reoperation during reconstruction. Pregnancy Consideration: In the case of childbearing women, individuals must provide a negative result on a pregnancy test and commit to using contraception throughout the clinical study period. Informed Consent: Participants must voluntarily provide written consent after receiving a comprehensive explanation of the clinical study. Exclusion Criteria: Pregnancy and Lactation: Pregnant or lactating women are excluded from participation in the study. Prior Thyroid or Airway Surgery: Individuals who have undergone thyroid or airway peripheral surgery before undergoing screening are ineligible for participation. Persistent Inflammation: Patients with ongoing inflammation of the thyroid or surrounding tissues at the time of screening are excluded. Systemic Inflammatory Disease: Patients diagnosed with systemic inflammatory diseases at the screening stage are not eligible to participate. Anesthesia Risk Factors: Individuals with a high risk of complications associated with general anesthesia due to existing liver disease, kidney disease, or heart disease are excluded. Sepsis: Patients diagnosed with sepsis at the time of screening are not eligible for participation. Hemorrhage Predisposition: Individuals with a predisposition to hemorrhage at the time of screening are excluded from the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sung Won Kim, MD, PhD
Organizational Affiliation
Seoul St. Mary's Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Seoul St. Mary's Hospital
City
Seoul
ZIP/Postal Code
06591
Country
Korea, Republic of

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
26041482
Citation
Park JH, Hong JM, Ju YM, Jung JW, Kang HW, Lee SJ, Yoo JJ, Kim SW, Kim SH, Cho DW. A novel tissue-engineered trachea with a mechanical behavior similar to native trachea. Biomaterials. 2015 Sep;62:106-15. doi: 10.1016/j.biomaterials.2015.05.008. Epub 2015 May 23.
Results Reference
result
PubMed Identifier
30261427
Citation
Park JH, Park JY, Nam IC, Ahn M, Lee JY, Choi SH, Kim SW, Cho DW. A rational tissue engineering strategy based on three-dimensional (3D) printing for extensive circumferential tracheal reconstruction. Biomaterials. 2018 Dec;185:276-283. doi: 10.1016/j.biomaterials.2018.09.031. Epub 2018 Sep 19.
Results Reference
result
PubMed Identifier
26163763
Citation
Park JH, Park JY, Nam IC, Hwang SH, Kim CS, Jung JW, Jang J, Lee H, Choi Y, Park SH, Kim SW, Cho DW. Human turbinate mesenchymal stromal cell sheets with bellows graft for rapid tracheal epithelial regeneration. Acta Biomater. 2015 Oct;25:56-64. doi: 10.1016/j.actbio.2015.07.014. Epub 2015 Jul 9.
Results Reference
result

Learn more about this trial

Patient-Customized Bioprinting Technology for Practical Regeneration of the Respiratory Tract (Trachea)

We'll reach out to this number within 24 hrs